Drug intelligence / Profile preview

BOL

Development stage: Preclinical
Lead developer: Agenus

Overview

BOL is a drug for which Agenus has licensed commercial rights to Zydus Pharmaceuticals (USA) Inc. for India and Sri Lanka. The transaction is intended to enhance Zydus's oncology portfolio, indicating that BOL is an oncology drug. Further details regarding its mechanism of action or specific indications are not available in the provided context.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on BOL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOL.

Explore the full profile